RxDoctor Payments Data

Michelle Khoo, MD

Cardiovascular Disease · Decatur, TXNPI 1245267236

Payments from drug & device makers

$67,842in general payments, 2019–2025

Across 724 payments — averaging $93.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$48K
  • Abbott$8K
  • E.r. Squibb & Sons, L.L.C.$3K
  • Novartis$1K
  • Johnson & Johnson$1K
  • Boston Scientific$1K
  • plus $5K from 25 others

What the payments were for

  • Consulting fees$2,9004%
  • Speaking & faculty fees$41,50061%
  • Travel & lodging$6,2119%
  • Food & beverage$17,21025%
  • Education$200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$67,842 in reported general payments places this provider in the 85th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$140,942
Medicare patients
256
Services billed
1,484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban229$226,123
XareltoRivaroxaban89$84,842
EntrestoSacubitril/Valsartan53$68,065
JardianceEmpagliflozin48$53,747
BrilintaTicagrelor40$24,815
FarxigaDapagliflozin Propanediol30$24,600
Flecainide Acetate99$4,066
Metoprolol Succinate286$4,014
Rosuvastatin Calcium120$1,756
Atorvastatin Calcium202$1,699
Amiodarone Hcl79$1,484
Carvedilol177$1,345
ClopidogrelClopidogrel Bisulfate129$1,176
Midodrine Hcl13$1,133
Lisinopril103$998

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$390$226,123229 claims
Johnson & JohnsonXarelto$1,044$84,84289 claims
NovartisEntresto$1,118$68,06553 claims
Boehringer IngelheimJardiance$927$53,74748 claims
AstraZenecaBrilinta, Farxiga$391$49,41570 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Decatur

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →